EDIT vs. PACB

In the year-to-date period, EDIT achieves a -87.66% return, which is significantly lower than PACB's -80.33% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current EDIT Sharpe Ratio is -1.16, which is lower than the PACB Sharpe Ratio of -0.68. The chart below compares the historical Sharpe Ratios of EDIT and PACB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither EDIT nor PACB has paid dividends to shareholders.

The maximum EDIT drawdown since its inception was -98.62%, roughly equal to the maximum PACB drawdown of -97.65%. Use the drawdown chart below to compare losses from any high point for EDIT and PACB. For additional features, visit the drawdowns tool.

Editas Medicine, Inc. (EDIT) has a higher volatility of 35.06% compared to Pacific Biosciences of California, Inc. (PACB) at 26.25%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than PACB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Editas Medicine, Inc. and Pacific Biosciences of California, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.